MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors
Bone Reports
· Elsevier
Аннотация
Publication date: September 2026 Source: Bone Reports, Volume 30 Author(s): G. Mammone, R. Coropciuc, T. Van den Wyngaert, R. Jacobs, P. Bossier, C. Kerkhofs, L. Wijnen, S. Meerschaert, E. Vissenaekens, P.M. Clement, O. Bechter, P.R. Debruyne, A. Laenen, B. Beuselinck
Читать у издателя →
Цитировать
Получайте новые статьи по теме «Эндокринология, диабет и метаболизм»
Подписка, поиск по ключевым словам и избранное — в Telegram-боте Articlium.
Открыть в Telegram
Цитирование
✕
ГОСТ
APA
MLA
BibTeX
MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors. // Bone Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2352187226000380?dgcid=rss_sd_all
MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Bone Reports. https://www.sciencedirect.com/science/article/pii/S2352187226000380?dgcid=rss_sd_all
“MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors.” Bone Reports.
@article{article38882,
title = {MRONJ risk associated with combined antiresorptive and vascular endothelial growth factor receptor tyrosine kinase inhibitors},
journal = {Bone Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2352187226000380?dgcid=rss_sd_all}
}